Last reviewed · How we verify
Islet Cell Transplant — Competitive Intelligence Brief
phase 3
Endocrinology
Small molecule
Live · refreshed every 30 min
Target snapshot
Islet Cell Transplant (Islet Cell Transplant) — University of Illinois at Chicago. Islet cell transplantation restores insulin-producing beta cells to the pancreas, enabling endogenous insulin secretion and glycemic control in patients with type 1 diabetes.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Islet Cell Transplant TARGET | Islet Cell Transplant | University of Illinois at Chicago | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Islet Cell Transplant CI watch — RSS
- Islet Cell Transplant CI watch — Atom
- Islet Cell Transplant CI watch — JSON
- Islet Cell Transplant alone — RSS
Cite this brief
Drug Landscape (2026). Islet Cell Transplant — Competitive Intelligence Brief. https://druglandscape.com/ci/islet-cell-transplant. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing